WASHINGTON (Reuters) – The U.S. Food and Drug Administration said on Wednesday it was reviewing Acadia Pharmaceuticals’ Parkinson’s medication, the only approved drug used to treat hallucinations and delusions associated with the disease.
Source: Reuters Medical News